Abstract 136P
Background
We conducted a multicenter, open-label, phase 2 study to evaluate TIS + platinum-based chemo (cohort 1) or TIS + mono-chemo + beva (cohort 2) in EGFR-mutated nsq-NSCLC pts who progressed on EGFR TKI therapies. Our previous results showed that both cohorts met the primary endpoint (1-year PFS rate). Here, we report the updated analysis with extended follow-up.
Methods
EGFR-mutated, nsq-NSCLC pts who had failed prior EGFR-TKIs received induction therapy with TIS + carboplatin (CBP) + nab-paclitaxel (nab-P; cohort 1) or TIS + nab-P + beva (cohort 2) every 3 weeks for 4 cycles, followed by maintenance therapy with TIS + pemetrexed (cohort 1) or TIS + beva (cohort 2) for up to 31 cycles.
Results
A total of 123 pts were enrolled (cohort 1, n=69; cohort 2, n=54). As of Aug 2, 2024, minimum study follow-up time (from the last patient’s first dose to data cutoff) was 32.3 and 17.1 mo, respectively for cohort 1 and cohort 2. Median OS was 27.1 mo in cohort 1, and 2-year and 3-year OS rates were 53.5% and 38.2%, respectively. For cohort 2, median OS was not reached, with 2-year OS rate of 61.4%. Pts with EGFR exon 21 L858R mutation had significantly longer OS than those with exon 19 deletion in cohort 1, while no similar trend was observed in cohort 2. Median PFS was 7.6 and 10.3 mo, respectively (Table). After prolonged follow-up, toxicity was manageable, with no new safety signals observed in both cohorts. Table: 136P
Cohort 1 TIS + CBP + nab-P | Cohort 2 TIS + nab-P+ beva | |
Minimum study follow-up time∗, mo | 32.3 | 17.1 |
Median OS, mo (95% CI) | 27.1 (17.5, 36.9) | NR (19.2, NE) |
OS rate, % (95% CI) | ||
1-year | 75.2 (62.2, 84.2) | 78.8 (65.1, 87.7) |
2-year | 53.5 (40.1, 65.1) | 61.4 (45.3, 74.1) |
3-year | 38.2 (24.9, 51.5) | NR (NE, NE) |
Median PFS, mo (95% CI) | 7.6 (5.8, 9.4) | 10.3 (6.4, 14.5) |
1-year PFS rate, % (90% CI) | 25.4 (16.4, 35.3) | 42.2 (30, 53.8) |
∗From the last patient’s first dose to data cutoff. NR, not reached; NE, not estimable.
Conclusions
TIS + platinum-based chemo (cohort 1) and TIS + mono-chemo + beva (cohort 2) demonstrated encouraging OS benefits and manageable toxicity for pts with EGFR-mutated nsq-NSCLC after EGFR TKI failure with extended follow-up. This study expands the treatment options for this patient population, allowing clinicians to tailor their choices based on individual patient circumstances.
Clinical trial identification
NCT04405674.
Legal entity responsible for the study
The authors.
Funding
BeiGene Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract